|
|
Blood, 1 July 2007, Vol. 110, No. 1, pp. 180-185.
Prepublished online as a Blood First Edition Paper on February 8, 2007; DOI 10.1182/blood-2006-11-060087.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
Fumihiko Tsushima1,
Sheng Yao1,
Tahiro Shin1,
Andrew Flies1,
Sarah Flies1,
Haiying Xu1,
Koji Tamada1,
Drew M. Pardoll2, and
Lieping Chen1,2
1 Department of Dermatology and
2 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
Although self-reactive T-cell precursors can be eliminated upon recognition of self-antigen presented in the thymus, this central tolerance process is often incomplete, and additional mechanisms are required to prevent autoimmunity. Recent studies indicates that the interaction between B7-H1 and its receptor PD-1 on activated T cells plays an important role in the inhibition of T-cell responses in peripheral organs. Here, we show that, before their exit to the periphery, T cells in lymphoid organs rapidly up-regulate PD-1 upon tolerogen recognition. Ablation of the B7-H1 and PD-1 interaction when T cells are still in lymphoid organs prevents anergy. Furthermore, blockade of B7-H1 and PD-1 interaction could render anergic T cells responsive to antigen. Our results thus reveal previously unappreciated roles of B7-H1 and PD-1 interaction in the control of initiation and reversion of T-cell anergy.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. N. Rivas, K. Weatherly, M. Hazzan, B. Vokaer, S. Dremier, F. Gaudray, M. Goldman, I. Salmon, and M. Y. Braun
Reviving Function in CD4+ T Cells Adapted to Persistent Systemic Antigen
J. Immunol.,
October 1, 2009;
183(7):
4284 - 4291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Wilcox, A. L. Feldman, D. A. Wada, Z.-Z. Yang, N. I. Comfere, H. Dong, E. D. Kwon, A. J. Novak, S. N. Markovic, M. R. Pittelkow, et al.
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
Blood,
September 3, 2009;
114(10):
2149 - 2158.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yao, S. Wang, Y. Zhu, L. Luo, G. Zhu, S. Flies, H. Xu, W. Ruff, M. Broadwater, I.-H. Choi, et al.
PD-1 on dendritic cells impedes innate immunity against bacterial infection
Blood,
June 4, 2009;
113(23):
5811 - 5818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chikuma, S. Terawaki, T. Hayashi, R. Nabeshima, T. Yoshida, S. Shibayama, T. Okazaki, and T. Honjo
PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
J. Immunol.,
June 1, 2009;
182(11):
6682 - 6689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. A. Parish, S. Rao, G. K. Smyth, T. Juelich, G. S. Denyer, G. M. Davey, A. Strasser, and W. R. Heath
The molecular signature of CD8+ T cells undergoing deletional tolerance
Blood,
May 7, 2009;
113(19):
4575 - 4585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. V. Parekh, S. Lalani, S. Kim, R. Halder, M. Azuma, H. Yagita, V. Kumar, L. Wu, and L. Van Kaer
PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells
J. Immunol.,
March 1, 2009;
182(5):
2816 - 2826.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-Y. Zhang, Z. Zhang, B. Jin, S.-Y. Zhang, C.-B. Zhou, J.-L. Fu, and F.-S. Wang
Cutting Edge: Programmed Death-1 Up-Regulation Is Involved in the Attrition of Cytomegalovirus-Specific CD8+ T Cells in Acute Self-Limited Hepatitis B Virus Infection
J. Immunol.,
September 15, 2008;
181(6):
3741 - 3744.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Botturi, Y. Lacoeuille, P. Thomas, S. Boniface, M. Reynaud-Gaubert, and A. Magnan
CTLA-4-mediated regulatory phenotype of T-cells in tolerant lung recipients
Eur. Respir. J.,
June 1, 2008;
31(6):
1167 - 1176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni, and A. Nagler
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
Clin. Cancer Res.,
May 15, 2008;
14(10):
3044 - 3051.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Azuma, S. Yao, G. Zhu, A. S. Flies, S. J. Flies, and L. Chen
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Blood,
April 1, 2008;
111(7):
3635 - 3643.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yoshida, F. Jiang, T. Honjo, and T. Okazaki
PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice
PNAS,
March 4, 2008;
105(9):
3533 - 3538.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Alderson, Q. Zhou, V. Berner, D. E. C. Wilkins, J. M. Weiss, B. R. Blazar, L. A. Welniak, R. H. Wiltrout, D. Redelman, and W. J. Murphy
Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy
J. Immunol.,
March 1, 2008;
180(5):
2981 - 2988.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|